{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:50:00Z","timestamp":1794963000112,"version":"4.9.1"},"reference-count":30,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective was to review the pharmacology, efficacy, and safety of intravenous ceftobiprole in the treatment of bloodstream infections, acute bacterial skin and skin structure infections (ABSSSIs), community-acquired pneumonia (CAP), and hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>PubMed and ClinicalTrials.gov were searched using the following terms: ceftobiprole, ceftobiprole medocaril, ceftobiprole medocaril sodium, Zevtera, and BAL5788.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Articles published in English between January 1985 and August 15, 2024, related to pharmacology, safety, efficacy, and clinical trials were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Ceftobiprole has shown similar efficacy to comparator antibiotics in CAP, ABSSSIs, and bloodstream infections. Overall treatment success in patients with bacteremia was 69.8% and 68.7%; 91.3% and 88.1% with ABSSSIs and 86.6% and 87.4% with CAP in ceftobiprole and comparator groups, respectively. Finally, in the management of HAP and VAP, ceftobiprole was inferior in the VAP population. Ceftobiprole had a favorable safety profile with gastrointestinal adverse effects occurring more frequently than comparators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n                    <jats:p>\n                      Clinicians have limited options to treat multidrug-resistant infections. Ceftobiprole has demonstrated efficacy against causative pathogens in specific infections including methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      bacteremia (SAB), ABSSSI, and CAP and may be considered a viable alternative. However, ceftobiprole\u2019s impact on HAP, VAP, and febrile neutropenia needs to be further delineated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Ceftobiprole\u2019s broad-spectrum activity makes it a viable option for treating patients hospitalized with CAP, ABSSSI, and SAB. Further studies are needed in severely ill HAP or VAP, febrile neutropenia, and pediatric patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241293773","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T05:11:27Z","timestamp":1733548287000},"page":"657-665","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Ceftobiprole Medocaril: A New Fifth-Generation Cephalosporin"],"prefix":"10.1177","volume":"59","author":[{"given":"Justin","family":"Zimmerman","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0540-785X","authenticated-orcid":false,"given":"Christopher","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA"},{"name":"Henry Ford St. John Hospital, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-7710","authenticated-orcid":false,"given":"Pramodini B.","family":"Kale-Pradhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA"},{"name":"Henry Ford St. John Hospital, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Center of Disease Control and Prevention. Antimicrobial Resistance Threats in the United States 2019. Accessed August 20 2024. https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1581"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12121692"},{"key":"e_1_3_2_5_2","unstructured":"Zevtera(ceftobiprolemedocaril)[packageinsert]. Basilea Pharmaceutica Ltd. Accessed August 19 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218275s000lbl.pdf"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.7.2570-2575.2004"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.48.7.2576-2580.2004"},{"key":"e_1_3_2_8_2","first-page":"11","article-title":"Ceftobiprole: pharmacokinetics and PK\/PD profile","volume":"32","author":"Azanza Perea JR","year":"2019","unstructured":"Azanza Perea JR, D\u00edaz de Rada BS. Ceftobiprole: pharmacokinetics and PK\/PD profile. Rev Esp Quimioter. 2019;32(suppl 3):11-16.","journal-title":"Rev Esp Quimioter"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00144-09"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/25.6.959"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01537-10"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27285"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847010-00003"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003296"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300220"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa974"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/526527"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.11.005"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu219"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.02.013"},{"issue":"11","key":"e_1_3_2_21_2","first-page":"631","article-title":"Ceftobiprole, a broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA)","volume":"33","author":"Kisgen J","year":"2008","unstructured":"Kisgen J, Whitney D. Ceftobiprole, a broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). Pharm Ther. 2008;33(11): 631-641.","journal-title":"Pharm Ther"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.08.016"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01181-06"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00724-06"},{"key":"e_1_3_2_25_2","first-page":"3","article-title":"Mechanisms of action and antimicrobial activity of ceftobiprole","volume":"32","author":"Morosini MI","year":"2019","unstructured":"Morosini MI, D\u00edez-Aguilar M, Cant\u00f3n R. Mechanisms of action and antimicrobial activity of ceftobiprole. Rev Esp Quimioter. 2019;32(suppl 3):3-10.","journal-title":"Rev Esp Quimioter"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00722-06"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0636-7"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003077"},{"key":"e_1_3_2_29_2","unstructured":"A study of ceftobiprole in patients with fever and neutropenia. ClinicalTrials.gov. Identifier: NCT00529282. Sponsor: Basilea Pharmaceutica; Study Director: Johnson & Johnson Pharmaceutical Research & Development L.L.C. Updated August 1 2012. Accessed August 19 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT00529282"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.07.021"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2021-0042"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241293773","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241293773","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241293773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:54Z","timestamp":1777374834000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241293773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/10600280241293773"],"URL":"https:\/\/doi.org\/10.1177\/10600280241293773","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,7]]}}}